Any concerns that this might trigger FDA to require us to run DMOAD trial before getting even an NDA approval for just pain and function? Which means date of product launch could be further delayed even though we would be able to charge more? Could we be opening pandora's box with this?
Ann: Investor Presentation - $66m Capital Raise, page-11
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $216.0K | 1.057M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 143324 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 44935 | 3 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |